Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by ScienceFirston Jan 31, 2023 10:35pm
389 Views
Post# 35258548

Moving to NASDAQ once FDA designation is granted

Moving to NASDAQ once FDA designation is grantedWith a FDA designation (Breakthrough Therapy or Accelerated Approval), we will move to NASDAQ, just like all the other biotechs.  This is where our market valuation will grow to fair valuation.

We will be able to raise capital so we can advance GBM, NSCLC and vaccine much faster and to prepare for marketing NMIBC, before a jv.  This will be seen as something very positive for our market valuation, in order to have more money in the kitty, ahead of big pharmas negociations for a jv on NMIBC rights.  If we want TLT to be independent in these negociations, that's what will have to happen.  Expect a road show after such FDA desingation.  The phone will start ringing with serious US brokage firms that are capable of bringing us much higher.

Raising money will be extremely positive at this stage as FDA designation will attract this time real hungry investors that will want to move us much higher in valuation.  Oncology innovations command 1B$US+ in market valuation, when you are a contender for the next SOC.
<< Previous
Bullboard Posts
Next >>